New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 200mg;  ;   - film coated tablet - 200 mg - active: topiramate 200mg     excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink ys-1-1456-g as opadry pink ys-1-1759-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 25mg;   - film coated tablet - 25 mg - active: topiramate 25mg   excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7706-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 50mg;  ;   - film coated tablet - 50 mg - active: topiramate 50mg     excipient: carnauba wax lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow ys-1-6370-g sodium starch glycolate starch - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 15mg;  ;   - capsule - 15 mg - active: topiramate 15mg     excipient: cellulose acetate gelatin opacode black s-1-17822 opacode black s-1-17823 povidone sucrose - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 25mg;  ;   - capsule - 25 mg - active: topiramate 25mg     excipient: cellulose acetate gelatin opacode black s-1-17822 opacode black s-1-17823 povidone sucrose - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - topiramate 50mg;  ;   - capsule - 50 mg - active: topiramate 50mg     excipient: cellulose acetate gelatin opacode black s-1-17822 opacode black s-1-17823 povidone sucrose - topamax is indicated in adults and children, 2 years and over: · as monotherapy in patients with newly diagnosed epilepsy · for conversion to monotherapy in patients with epilepsy · as add-on therapy in partial onset seizures, generalised tonic-clonic seizures or seizures associated with lennox-gastaut syndrome.

United States - English - NLM (National Library of Medicine)

valeant pharmaceuticals, inc. - pergolide (unii: 24mj822nz9) (pergolide - unii:24mj822nz9) - tablet - 0.05 mg - permax is indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of parkinson's disease. evidence to support the efficacy of pergolide as an antiparkinsonian adjunct was obtained in a multicenter study enrolling 376 patients with mild to moderate parkinson's disease who were intolerant to l -dopa/carbidopa as manifested by moderate to severe dyskinesia and/or on-off phenomena. on average, the patients evaluated had been on l -dopa/carbidopa for 3.9 years (range, 2 days to 16.8 years). the administration of pergolide permitted a 5% to 30% reduction in the daily dose of l -dopa. on average, these patients treated with pergolide maintained an equivalent or better clinical status than they exhibited at baseline. pergolide is contraindicated in patients who are hypersensitive to this drug or other ergot derivatives.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

enviromax technologies pty ltd - imidacloprid; (z)-9 tricosene - granular formulation - imidacloprid guanidine active 5.0 g/kg; (z)-9 tricosene biological-pheromone-insect active 1.0 g/kg - insecticide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

max(rudong) chemicals co., ltd. - ethephon - aqueous concentrate - ethephon organophosphorus active 720.0 g/l - growth regulator

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

max(rudong) chemicals co., ltd. - picloram present as the hexyloxypropylamine salt; triclopyr present as the butoxyethyl ester - emulsifiable concentrate - picloram present as the hexyloxypropylamine salt anilide/aniline-pyrimidine active 100.0 g/l; triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 300.0 g/l - herbicide